Mr Mrs Miss Ms Dr Other

Mr
David
Akerman

Senior Patent Attorney

Newcastle Office York Office

Technology & Engineering

Telephone. +44(0) 191 205 8360
Email. dakerman@hgf.com

Experience

David’s wide-ranging IP experience includes undertaking patent searching and freedom to operate projects, patent drafting and prosecution, and developing IP strategies to match the commercial priorities of a business.

Before qualifying as a UK and European Patent Attorney, David gained 20 years' IP management experience through in-house roles in textile and consumer-goods companies who were making significant investment in innovation and IP.

David has had significant involvement in contentious IP matters in Europe, USA and Japan, including disputes involving patents, designs, trade dress, breach of confidence and know how. He has also had involvement in IP due diligence in company and asset purchase projects.

After graduating from the University of Manchester, Institute of Science and Technology with an honours degree in Chemistry, David stayed on to undertake a PhD in Textile Chemistry. His research investigated the mechanism of oxidative bleaching of dyed cotton substrates during domestic laundering. The project was funded by industry and led to the publication of a patent application and three academic papers.

Qualifications

Patent Attorney

Chartered (UK)
Europe


BSC

Chemistry

PHD

Textile Chemistry

POSTGRADUATE DIPLOMA OR CERTIFICATE

PG Certificate in Intellectual Property

Related News

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

The concept of ‘overall impression’ in UK and EU Registered Design Law

 

Read article

The Antibody Series #2 | Definition via binding strength in antibody claims: when “binds strongly... but only minimally...” becomes a trap of lack of clarity

Introduction Defining an antibody by its binding strength is common practice in patent claims, but it can quickly become a pitfall under Article 84 EPC on clarity. In this second …

Read article

The Antibody Series #1 | Quality Characteristics (CQAs) in Antibody Claims: When the Test Method Can Remain Outside the Claim

Introduction Therapeutic antibodies are at the heart of innovations in biotechnology and healthcare. With increasing regulatory requirements and quality expectations, critical quality attributes (CQAs) are becoming essential in the drafting …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.